NEW YORK, Jan. 27, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of SciClone Pharmaceuticals, Inc. ("SciClone" or the "Company") (NasdaqGS: SCLN). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at firstname.lastname@example.org or 212-697-6484. The investigation concerns whether SciClone and certain of its officers and/or directors have violated federal securities laws. On January 24, 2014, SciClone announced in a regulatory filing that "during the year ended December 31, 2012, the Company identified deficiencies in the design and operating effectiveness of controls primarily associated with the timing of revenue recognition for its Pfizer products and product returns reserves related to its Aggrastat product line, the override of certain controls in the financial statement close process related to its NovaMed subsidiary, and the corporate monitoring thereof." On this news shares of the SciClone fell $.54 or 10.51% during intraday trading to trade at $4.60 On January 27, 2014. If you are aware of any facts relating to this investigation, or purchased shares of SciClone you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.